Kate W Grimsrud1, Rashmi B Halker Singh2. 1. Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA. grimsrud.kate@mayo.edu. 2. Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to evaluate and describe recent and emerging treatment options for episodic migraine. RECENT FINDINGS: Recent advances have been made in better understanding the pathophysiology of migraine, which has led to further investigation of potential new pharmacologic and non-pharmacologic treatment options. A number of new medications are emerging for the acute and preventive treatment of migraine, including CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT1F agonists, and PACAP receptor monoclonal antibodies. Additionally, newer studies on existing non-invasive neuromodulation devices including transcranial magnetic stimulation, supraorbital transcutaneous nerve stimulation, and transcutaneous vagus nerve stimulation have recently received FDA approval for use in migraine. Neuromodulation devices including percutaneous mastoid electrical stimulation, non-painful remote electrical stimulation, and caloric vestibular stimulation are undergoing further investigation and have shown promising results thus far. These new developments are expected to contribute to better treatment and decreased disability in migraine.
PURPOSE OF REVIEW: The purpose of this review is to evaluate and describe recent and emerging treatment options for episodic migraine. RECENT FINDINGS: Recent advances have been made in better understanding the pathophysiology of migraine, which has led to further investigation of potential new pharmacologic and non-pharmacologic treatment options. A number of new medications are emerging for the acute and preventive treatment of migraine, including CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT1F agonists, and PACAP receptor monoclonal antibodies. Additionally, newer studies on existing non-invasive neuromodulation devices including transcranial magnetic stimulation, supraorbital transcutaneous nerve stimulation, and transcutaneous vagus nerve stimulation have recently received FDA approval for use in migraine. Neuromodulation devices including percutaneous mastoid electrical stimulation, non-painful remote electrical stimulation, and caloric vestibular stimulation are undergoing further investigation and have shown promising results thus far. These new developments are expected to contribute to better treatment and decreased disability in migraine.
Authors: Stephen D Silberstein; David W Dodick; Marcelo E Bigal; Paul P Yeung; Peter J Goadsby; Tricia Blankenbiller; Melissa Grozinski-Wolff; Ronghua Yang; Yuju Ma; Ernesto Aycardi Journal: N Engl J Med Date: 2017-11-30 Impact factor: 91.245
Authors: David Wilkinson; Kristen K Ade; Lesco L Rogers; Deborah K Attix; Maragatha Kuchibhatla; Martin D Slade; Lanty L Smith; Kathryn P Poynter; Daniel T Laskowitz; Marshall C Freeman; Michael E Hoffer; Joel R Saper; Dianne L Scott; Mohamed Sakel; Anne H Calhoun; Robert D Black Journal: Headache Date: 2017-06-27 Impact factor: 5.887
Authors: Tiffini Voss; Richard B Lipton; David W Dodick; Nicole Dupre; Joy Yang Ge; Robert Bachman; Christopher Assaid; Sheena K Aurora; David Michelson Journal: Cephalalgia Date: 2016-06-06 Impact factor: 6.292
Authors: David W Dodick; Messoud Ashina; Jan Lewis Brandes; David Kudrow; Michel Lanteri-Minet; Vera Osipova; Kerry Palmer; Hernan Picard; Daniel D Mikol; Robert A Lenz Journal: Cephalalgia Date: 2018-02-22 Impact factor: 6.292